SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients ...

Dana-Farber researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Past efforts to collect data and to understand the relationship between minimal residual disease and outcomes will allow help ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Historically, more than half of patients with GM2 gangliosidosis need to be fed via IV between 13 and 18 months of age. In ...